No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder

Étain, Bruno; Roy, Isabelle; Henry, Chantal; Rousseva, Angela; Schürhoff, Franck; Leboyer, Marion; Bellivier, Frank

doi:10.1111/j.1399-5618.2007.00413.x

Cited by 15 publications

(7 citation statements)

References 29 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings have been mixed, likely due to varied clinical states of the patients and also sampling and measurement factors. As would be expected, anhedonia is prevalent among BP patients in the depressed phase (52%; Mazza et al, 2009), and while the rate is much lower among euthymic patients (12% - 20.5%), it is still significantly higher than healthy controls (Etain et al, 2007; Di Nicola et al, 2013). In mood induction studies, BP patients have shown sustained elevations of positive emotions across positive, neutral, and negative contexts compared to controls (Farmer et al, 2006; Gruber et al, 2008, 2011a).…”

Section: Introductionmentioning

confidence: 54%

“…For example, Blanchard et al (1994) found higher levels of physical and social anhedonia (as measured with the traditional Chapman scales) in SZ compared to a small sample of BP patients in manic or mixed state. Schürhoff et al (2003) and Etain et al (2007) also observed higher physical anhedonia in euthymic SZ compared to euthymic or recently manic BP. However, duration of illness and affective symptoms of the two clinical groups were often not well matched, calling for replications with samples better matched for these variables.…”

Section: Introductionmentioning

confidence: 82%

See 1 more Smart Citation

Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder

Tso

Grove

Taylor

2014

Psychiatry Research

View full text Add to dashboard Cite

The Kraepelinian distinction between schizophrenia (SZ) and bipolar disorder (BP) emphasizes affective and volitional impairment in the former, but data directly comparing the two disorders for hedonic experience are scarce. This study examined whether hedonic experience and behavioral activation may be useful phenotypes distinguishing SZ and BP. Participants were 39 SZ and 24 BP patients without current mood episode matched for demographics and negative affect, along with 36 healthy controls (HC). They completed the Chapman Physical and Social Anhedonia Scales, Temporal Experience of Pleasure Scale (TEPS), and Behavioral Activation Scale (BAS). SZ and BP showed equally elevated levels of self-report negative affect and trait anhedonia compared to HC. However, SZ reported significantly lower pleasure experience (TEPS) and behavioral activation (BAS) than BP, who did not differ from HC. SZ and BP showed differential patterns of relationships between the hedonic experience and behavioral activation measures. Overall, the results suggest that reduced hedonic experience and behavioral activation may be effective phenotypes distinguishing SZ from BP even when affective symptoms are minimal. However, hedonic experience differences between SZ and BP are sensitive to measurement strategy, calling for further research on the nature of anhedonia and its relation to motivation in these disorders.

show abstract

Section: Introductionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 82%

Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder

Tso

Grove

Taylor

2014

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“… 18 , 19 Furthermore, Sherdell et al 20 found that MDD patients experienced the same levels of pleasure as healthy volunteers while viewing humorous cartoons in a computer task, but were not willing to exert as much effort to gain access to these stimuli; the results suggest intact consummatory processes, but attenuated motivational ones. In another study, Etain et al 21 found no evidence for consummatory anhedonia in BD patients. Although research pertaining to BD patients in particular is lacking, overall, the extant evidence suggests that anhedonia in depression is primarily associated with a deficit in non-consummatory reward behaviors.…”

Section: Introductionmentioning

confidence: 91%

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

et al. 2014

View full text Add to dashboard Cite

Anhedonia—which is defined as diminished pleasure from, or interest in, previously rewarding activities—is one of two cardinal symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of anhedonia. Notably, over half of patients diagnosed with bipolar disorder experience significant levels of anhedonia during a depressive episode. Recent research into novel and rapid-acting therapeutics for depression, particularly the noncompetitive N-Methyl-D-aspartate receptor antagonist ketamine, has highlighted the role of the glutamatergic system in the treatment of depression; however, it is unknown whether ketamine specifically improves anhedonic symptoms. The present study used a randomized, placebo-controlled, double-blind crossover design to examine whether a single ketamine infusion could reduce anhedonia levels in 36 patients with treatment-resistant bipolar depression. The study also used positron emission tomography imaging in a subset of patients to explore the neurobiological mechanisms underpinning ketamine's anti-anhedonic effects. We found that ketamine rapidly reduced the levels of anhedonia. Furthermore, this reduction occurred independently from reductions in general depressive symptoms. Anti-anhedonic effects were specifically related to increased glucose metabolism in the dorsal anterior cingulate cortex and putamen. Our study emphasizes the importance of the glutamatergic system in treatment-refractory bipolar depression, particularly in the treatment of symptoms such as anhedonia.

show abstract

“…(Gorwood, 2008). The research evidence so far points to anhedonia being a potential endophenotype for depression and schizophrenia, but not for bipolar disorder (Etain et al, 2007; McCabe et al, 2009; Shankman et al, 2010; Wacker et al, 2009).…”

Section: State or Traitmentioning

confidence: 99%

Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?

2013

View full text Add to dashboard Cite

It is 16 years since we reviewed anhedonia in depression. Since then, there have been important developments in the study of anhedonia, mainly using the new techniques that neuroimaging made available, which provide very interesting new insights. It is becoming increasingly apparent that anhedonia, with psychomotor retardation, defines a dimension in depressive disorder that seems to be distinct from a dimension encompassing mood plus somatic symptoms. These dimensions can coexist, but may also be present separately. The first appears associated with disturbances (under-functioning) in dopamine function; the other appears to be related to a similar under-functioning in the serotonin system. Furthermore, anhedonia itself increasingly appears to be a composite symptom, consisting of at least two dimensions (i.e. a motivational/appetitive and a consummatory one). Depression appears to be characteristically linked more to the first one, in contrast to what was originally thought. We discuss the significance of the above in the evolving treatment of depression and the potential use of dopamine-targeting drugs.

show abstract

No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder

Cited by 15 publications

References 29 publications

Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder

Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?

Contact Info

Product

Resources

About